Our top pick for
Cleveland BioLabs, Inc is a biotechnology business based in the US. Cleveland BioLabs shares (CBLI) are listed on the NASDAQ and all prices are listed in US Dollars. Cleveland BioLabs employs 7 staff and has a trailing 12-month revenue of around USD$631,842.
|Latest market close||USD$2.74|
|52-week range||USD$0.515 - USD$4.65|
|50-day moving average||USD$3.0591|
|200-day moving average||USD$2.4721|
|Wall St. target price||USD$2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.268|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||-26.74%|
|1 month (2020-12-18)||-3.52%|
|3 months (2020-10-19)||26.27%|
|6 months (2020-07-17)||1.11%|
|1 year (2020-01-17)||156.07%|
|2 years (2019-01-18)||87.67%|
|3 years (2018-01-19)||3.74|
|5 years (2016-01-19)||3.32|
|Gross profit TTM||USD$-543,006|
|Return on assets TTM||-47.85%|
|Return on equity TTM||-110.49%|
|Market capitalisation||USD$48.4 million|
TTM: trailing 12 months
There are currently 247,530 Cleveland BioLabs shares held short by investors – that's known as Cleveland BioLabs's "short interest". This figure is 7.2% down from 266,787 last month.
There are a few different ways that this level of interest in shorting Cleveland BioLabs shares can be evaluated.
Cleveland BioLabs's "short interest ratio" (SIR) is the quantity of Cleveland BioLabs shares currently shorted divided by the average quantity of Cleveland BioLabs shares traded daily (recently around 124386.93467337). Cleveland BioLabs's SIR currently stands at 1.99. In other words for every 100,000 Cleveland BioLabs shares traded daily on the market, roughly 1990 shares are currently held short.
However Cleveland BioLabs's short interest can also be evaluated against the total number of Cleveland BioLabs shares, or, against the total number of tradable Cleveland BioLabs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cleveland BioLabs's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Cleveland BioLabs shares in existence, roughly 20 shares are currently held short) or 0.0384% of the tradable shares (for every 100,000 tradable Cleveland BioLabs shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cleveland BioLabs.
Find out more about how you can short Cleveland BioLabs stock.
We're not expecting Cleveland BioLabs to pay a dividend over the next 12 months.
Cleveland BioLabs's shares were split on a 1:20 basis on 28 January 2015. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cleveland BioLabs shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cleveland BioLabs shares which in turn could have impacted Cleveland BioLabs's share price.
Over the last 12 months, Cleveland BioLabs's shares have ranged in value from as little as $0.515 up to $4.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cleveland BioLabs's is 0.705. This would suggest that Cleveland BioLabs's shares are less volatile than average (for this exchange).
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in mitigation of radiation injury, radiation oncology, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and other indications in radiation oncology. It is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, and Everon Biosciences. The company was founded in 2003 and is headquartered in Buffalo, New York.
Steps to owning and managing DRIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing CYBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHCI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing CKX, with 24-hour and historical pricing before you buy.
Steps to owning and managing CHA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTHR, with 24-hour and historical pricing before you buy.
Steps to owning and managing CNBKA, with 24-hour and historical pricing before you buy.
Steps to owning and managing CATM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRME, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.